logo
Why ENPH Stock Has Crashed 70%?

Why ENPH Stock Has Crashed 70%?

Forbes2 days ago

HOUSTON, TEXAS - FEBRUARY 14: Solar panels on the roof of Tom Cook's home on Fri, Feb 14, 2025, in ... More Bandera, Texas. (Christopher Lee/Houston Chronicle via Getty Images)
Enphase Energy (NASDAQ: ENPH), a prominent provider of residential solar energy solutions, has experienced a significant decline in its stock, falling nearly 40% this year and over 70% from its 52-week peak of around $140. What factors are contributing to this substantial drop? The company is facing a harsh mix of industry challenges and its own operational difficulties that have formed a perfect storm.
The primary issue impacting Enphase has been the drop in residential solar demand. The firm's revenue has taken a hit, decreasing 42% from $2.29 billion in 2023 to just $1.33 billion in 2024. This isn't solely an Enphase issue—it's occurring throughout the entire residential solar market as customers have largely refrained from making significant solar investments. It is precisely this downside risk, compared to the relative upside trade-offs we made – at scale, in constructing the Trefis High Quality (HQ) strategy that has achieved over 91% returns since its inception and outperformed the S&P. Additionally, see – Buy, Sell, or Hold HIMS Stock?
High interest rates are a significant factor, raising the costs for homeowners to finance solar installations. When faced with a solar system costing over $10,000 and skyrocketing borrowing costs, many individuals are simply saying, 'not now.' To complicate matters, the company is burdened with excess inventory. Similar to many solar companies, Enphase accumulated stock based on the expectation of stronger demand that has not materialized, adding more stress to the company's margins. As a result, Enphase's operating margin fell from 20% in 2023 to below 7% last year.
The earnings situation has also been difficult. Enphase consistently falls short of Wall Street's expectations, and their guidance isn't instilling much optimism in investors. In the last quarter, they reported earnings of $0.68 per share on $356 million in revenue, failing to meet predictions of $0.71 per share on $362 million in revenue. Even more troubling, management projected just $360 million in Q2 sales at the midpoint, significantly lower than the $380 million analysts were anticipating.
Moreover, there's the tariff situation. New tariffs of up to 3,500% on solar components—particularly battery cells from China and Southeast Asia—are poised to severely impact Enphase's profit margins. The company has already indicated that these tariffs will affect margins in the upcoming quarters, with an even greater negative effect expected later this year. They are attempting to move battery cell production from China to the U.S. to avoid the tariffs and secure some tax credits, but this transition requires time and resources. In the meantime, margins may suffer by several hundred basis points.
The general economic landscape isn't providing any relief either. With high interest rates and growing concerns about the economy, homeowners are understandably cautious about making large purchases like solar panels. This kind of environment typically leads to reductions in discretionary spending.
Enphase has attempted to address the situation by reducing costs, including laying off 500 employees and terminating some manufacturing contracts late last year. However, these actions merely underscore how challenging the circumstances have become and have not succeeded in convincing investors that brighter days lie ahead.
The bottom line is that Enphase finds itself in a challenging predicament. The company needs a rebound in residential solar demand and for the tariff situation to stabilize before any improvements can be seen. Until then, the stock will likely continue to experience pressure from both the fundamental business issues and investor doubts about when—or if—the solar market will recover. In fact, the predicament of Enphase Energy illustrates the risks of heavily investing in a single stock. Establishing a diversified portfolio is essential for balancing risk and reward. For instance, the Trefis High Quality (HQ) strategy, which emphasizes risk-reward balance, has consistently outperformed the S&P 500, Nasdaq, and Russell 2000 since its inception.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Samsung loses exclusivity over overclocked Snapdragon 8 Elite, thanks to this phone
Samsung loses exclusivity over overclocked Snapdragon 8 Elite, thanks to this phone

Android Authority

time26 minutes ago

  • Android Authority

Samsung loses exclusivity over overclocked Snapdragon 8 Elite, thanks to this phone

Supplied by REDMAGIC TL;DR REDMAGIC has announced the REDMAGIC 10S Pro gaming phone. This is the first non-Samsung phone to feature an overclocked Snapdragon 8 Elite chipset, but it also has a cooling fan. The new phone starts at $699 and is broadly available via the company's website. The Samsung Galaxy S25 phones use the Snapdragon 8 Elite for Galaxy chipset, which is an overclocked version of the flagship processor. Now, the first non-Samsung phone has arrived with an overclocked Snapdragon 8 Elite chip, and it might be the performance king of 2025. REDMAGIC has announced the REDMAGIC 10S Pro, and it indeed has the so-called Snapdragon 8 Elite Leading Version processor. This offers a peak CPU clock speed of 4.47GHz and a peak GPU frequency of 1.2GHz. By contrast, the standard Snapdragon 8 Elite chip tops out at 4.32GHz and 1.1GHz, respectively. Our own testing previously showed that several phones with the standard Snapdragon 8 Elite processor overheated during GPU stress tests. Fortunately, REDMAGIC's new phone offers a cooling fan (24,000RPM) to keep temperatures down. But even the presence of a fan wasn't enough to stop the earlier REDMAGIC 10 Pro from severely throttling and delivering sky-high temperatures. So I'm not feeling optimistic about the 10S Pro's sustained performance under heavy load. Nevertheless, you still have other cooling measures like a large vapor chamber and 'Liquid Metal 2.0' tech. REDMAGIC 10S Pro: What else does it have? Supplied by REDMAGIC The gaming-related features don't end here. You can also expect capacitive shoulder triggers, RGB lighting, and a so-called Magic Key that takes you to the GameSpace menu by default. Thankfully, this button can be customized for other tasks. The REDMAGIC 10S Pro also offers a 7,050mAh battery, which should deliver long endurance on paper for your gaming sessions. This is paired with 80W wired charging via a bundled charger. Just don't expect wireless charging here. Other notable features include a 6.85-inch 144Hz OLED screen (1.5K) with a 16MP under-display selfie camera, a 50MP+50MP+2MP triple rear camera system, an IR blaster, and REDMAGIC OS 10.5 atop Android 15. A closer look at the phone also reveals the welcome presence of a headphone jack. REDMAGIC 10S Pro pricing and availability The good news is that this gaming phone will be available in a variety of markets, including the US, via the REDMAGIC website. Other notable locales include Asia-Pacific markets, Europe, the Middle East, and the UK. The REDMAGIC 10S Pro starts at $699 / £579 / €649 for the base 12GB/256GB model. Meanwhile, the top-end 24GB/1TB model costs $999 / £879 / €999. REDMAGIC added that it's also offering early bird pricing of $649 from June 17. Got a tip? Talk to us! Email our staff at Email our staff at news@ . You can stay anonymous or get credit for the info, it's your choice.

Simulations Plus Releases ADMET Predictor® 13
Simulations Plus Releases ADMET Predictor® 13

Yahoo

time26 minutes ago

  • Yahoo

Simulations Plus Releases ADMET Predictor® 13

Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment RESEARCH TRIANGLE PARK, N.C., June 05, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. "ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space," said David Miller, Vice President of Cheminformatics of Simulations Plus. "Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world." Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AMD Acquires Another Company To Expand AI Arsenal
AMD Acquires Another Company To Expand AI Arsenal

Yahoo

time27 minutes ago

  • Yahoo

AMD Acquires Another Company To Expand AI Arsenal

Advanced Micro Devices, Inc (NASDAQ:AMD) on Wednesday announced the acquisition of Brium, a team of compiler and AI software experts with deep expertise in machine learning, AI inference, and performance optimization. The financial terms of the transaction remain undisclosed. Brium brings advanced software capabilities that strengthen AMD's ability to deliver highly optimized AI solutions across the entire stack. Their work in compiler technology, model execution frameworks, and end-to-end AI inference optimization will play a key role in enhancing the efficiency and flexibility of AMD's AI acquisition marks the latest in a series of targeted investments, following AMD's acquisitions of Silo AI, and Mipsology, that boosts its ability to support the open-source software ecosystem and deliver optimized performance on its hardware. Last week, AMD announced the acquisition of Enosemi, a move to accelerate co-packaged optics innovation for AI systems. The financial terms of the deal remain undisclosed. AMD held $6.06 billion in cash and equivalents as of March 29, 2025. AMD stock plunged 29% in the last 12 months as it grappled with intensifying rivalry from Nvidia Corp (NASDAQ:NVDA), a cooling tech rally, and the Trump administration's tariff policies. AMD reported first-quarter revenue of $7.44 billion, up 36%, beating analyst estimates of $7.13 billion. The chipmaker reported first-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 94 cents per share. AMD expects second-quarter revenue of approximately $7.4 billion, plus or minus $300 million. Analysts are currently forecasting second-quarter revenue of $7.24 billion. Price Action: AMD stock is trading higher by 0.42% to $119.08 premarket at last check Thursday. Read Next:Photo by jamesonwu1972 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ADVANCED MICRO DEVICES (AMD): Free Stock Analysis Report This article AMD Acquires Another Company To Expand AI Arsenal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store